What is the administration protocol for alteplase (tissue plasminogen activator) in massive pulmonary embolism, specifically when giving 10% of the total dose as an initial bolus?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alteplase Administration Protocol for Massive Pulmonary Embolism

Direct Answer

No, do not give 10% of the total dose first as a bolus for massive pulmonary embolism—the FDA-approved regimen is 100 mg administered as a continuous intravenous infusion over 2 hours without an initial bolus. 1

Critical Distinction: Stroke vs. Pulmonary Embolism Protocols

The 10% bolus protocol you're referencing is exclusively for acute ischemic stroke, not pulmonary embolism:

  • For stroke: Administer 0.9 mg/kg (maximum 90 mg) over 60 minutes, with 10% given as a bolus over 1 minute 2
  • For massive PE: Administer 100 mg as a continuous infusion over 2 hours with no initial bolus 1

This is a common and dangerous pitfall—confusing stroke and PE protocols can lead to inappropriate dosing.

Recommended Dosing for Massive PE

Standard regimen for hemodynamically unstable patients:

  • 100 mg alteplase administered as continuous IV infusion over 2 hours 1
  • Administer via peripheral IV catheter 1
  • Withhold heparin anticoagulation during the 2-hour infusion 1
  • Resume anticoagulation after completion of alteplase 1

Alternative regimens based on clinical severity:

For cardiac arrest or rapidly deteriorating condition due to massive PE:

  • 50 mg alteplase as IV bolus 1

For hemodynamically stable patients with confirmed massive PE:

  • 100 mg over 90 minutes (accelerated MI regimen) 1

Evidence Supporting the 2-Hour Infusion

The continuous infusion approach is supported by multiple lines of evidence:

  • The 100 mg/2-hour regimen has been directly compared to other thrombolytics and shown equivalent or superior efficacy 3
  • Studies using reduced-dose bolus regimens (0.6 mg/kg over 15 minutes) showed efficacy but did not demonstrate superiority over the standard 2-hour infusion 4, 5
  • The 2-hour infusion provides sustained thrombolytic effect with acceptable bleeding risk (10-40% minor bleeding complications) 1

Pediatric Considerations

If treating pediatric patients, different protocols apply:

  • 0.1-0.6 mg/kg/hour IV for 6 hours, OR 2
  • 0.2 mg/kg IV bolus (maximum 15 mg), then 0.75 mg/kg over 30 minutes (maximum 50 mg), followed by 0.5 mg/kg over 60 minutes (maximum 35 mg), with maximum total dose 100 mg 2

Clinical Decision Algorithm

Step 1: Confirm massive PE

  • Sustained hypotension, shock index >1.0, or respiratory failure 1
  • Imaging confirmation preferred, but may proceed with high clinical suspicion and RV dysfunction on bedside echo if patient too unstable for imaging 1

Step 2: Assess contraindications

  • Absolute: Active bleeding, recent stroke, current GI hemorrhage 2
  • Relative: Recent surgery (within 7 days), peptic ulcer disease, prolonged CPR 2
  • In life-threatening PE, contraindications may need reconsideration given high mortality without treatment 1

Step 3: Select appropriate regimen

  • Hemodynamically unstable but not arresting: 100 mg over 2 hours 1
  • Cardiac arrest/extreme instability: 50 mg bolus 1

Step 4: Anticoagulation management

  • Hold heparin during infusion 1
  • Resume after completion 1

Monitoring Requirements

  • Prepare for bleeding complications (10-40% incidence) 1
  • No intracranial hemorrhage occurred in major trials of the 100 mg/2-hour regimen 6
  • Major bleeding occurred in 15% of patients in bolus regimen studies 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.